Bioequivalence study on aqueous humour concentrations of active ingredients after topical application of LEVIOSA® versus F2904. Randomized, parallel-group, blinded-assessor study in patients undergoing cataract surgery – BreAK Free

2023-503722-39-00 Protocol LevodesaPF_01-2023 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 22 Apr 2024 · End 20 Mar 2025 · Status Ended · 1 EU/EEA countries · 3 sites · Protocol LevodesaPF_01-2023

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 90
Countries 1
Sites 3

Cataract

Key facts

Sponsor
Ntc S.r.l.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Eye Diseases [C11]
Trial duration
22 Apr 2024 → 20 Mar 2025
Decision date (initial)
2024-02-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Cataract

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Ntc S.r.l.

Sponsor organisation
Ntc S.r.l.
Address
Via Luigi Razza 3
City
Milan
Postcode
20124
Country
Italy

Scientific contact point

Organisation
Ntc S.r.l.
Contact name
Dr. Alessandro Colombo

Public contact point

Organisation
Ntc S.r.l.
Contact name
Dr. Alessandro Colombo

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ended 90 3
Rest of world 0

Investigational sites

Italy

3 sites · Ended
Azienda Sociosanitaria Territoriale Santi Paolo E Carlo
Clinica Oculistica, Via Antonio Di Rudini' 8, 20142, Milan
Universita' Degli Studi Di Verona
Unità Operativa Complessa di Oculistica, Piazzale Ludovico Antonio Scuro 10, 37134, Verona
Azienda Ospedaliero Universitaria Pisana
Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell'Area Critica, Via Paradisa 2, 56124, Pisa

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2024-04-22 2025-03-20 2024-05-03 2024-09-25

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-10-12 Italy Acceptable
2024-02-09
2024-02-09
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-06-13 Italy Acceptable
2024-02-09
2024-06-13
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-07-30 Italy Acceptable
2024-02-09
2024-07-30
4 NON SUBSTANTIAL MODIFICATION NSM-4 2024-12-19 Italy Acceptable
2024-02-09
2024-12-19